Jun 5, 2013 BAHCALL SAFI R
10,000 Direct Purchase at $4.04 per share. 40,400
Jun 5, 2013 KOVNER BRUCE
738,900 Indirect Purchase at $4.31 per share. 3,184,659
Jun 4, 2013 VUKOVIC VOJO
10,000 Direct Purchase at $4.58 per share. 45,800
Jun 4, 2013 KOVNER BRUCE
756,000 Indirect Purchase at $4.71 per share. 3,560,760
Jun 3, 2013 WILSON ROBERT N
10,000 Direct Purchase at $5 per share. 50,000
Jun 3, 2013 KOVNER BRUCE
505,100 Indirect Purchase at $4.99 per share. 2,520,449
mathwiz: i was looking at ther website under clinical trials and one of their drugs the last date to collect info is Sept 2013 so maybe the patients who are receiving both of the drugs together are doing really good. Maybe that is why the insiders bought? sure it only take 5 moonths or so to see how the patients are reacting to a new drug and maybe the cancer is gone? I have to study up on it some more.
Yep. The only problem is the book value is low and the cash burn rate is around $40-60M per year with no revenue. They have enough cash to last for a while though. Insiders probably know that the trials are very good or they wouldn't buy with this amount. If the trials are as good as it seems, then this thing can potentially pop up near $12 within a few weeks, if not much higher. Unfortunately the FED announcement hurt it a bit more.